Kumagai Gentaro, Wada Kanichiro, Asari Toru, Nitobe Yoshiro, Aburakawa Kotaro, Ishibashi Yasuyuki
Department of Orthopaedic Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Spine Surg Relat Res. 2024 May 10;8(6):568-574. doi: 10.22603/ssrr.2024-0017. eCollection 2024 Nov 27.
This study aimed to standardize perioperative interruption of antiplatelet agents in patients undergoing cervical spinal surgery and investigate the incidence of epidural hematoma and thrombotic complications.
A total of 153 patients, consisting of 85 men and 68 women, were included in this study. Their mean age was 65.5 years. They were divided into two groups: Groups A and B. Group A (139 patients) did not receive preoperative antiplatelet agents, and Group B (14 patients) resumed antiplatelet agents from 7 or 14 days presurgery to 3 days postsurgery. Our analysis encompassed demographic data before surgery, postoperative magnetic resonance image-based assessment of radiological epidural hematoma (EH), and complications such as symptomatic hematoma, blood transfusion, stroke, and venous thromboembolism after surgery.
The frequency of medical conditions, such as hypertension, diabetes, and hyperlipidemia, was significantly higher in Group B than in Group A. The CHADS2 scores, which serve as a clinical prediction rule for estimating stroke risk, were significantly higher in Group B than in Group A. In contrast, the intraoperative blood loss was significantly lower in Group B than in Group A. There was no significant difference in radiologically severe EH, hemorrhage, and thrombotic complications between the two groups. Interestingly, none of the patients in Group B had hemorrhagic and thrombotic complications.
Our standardized perioperative management of antiplatelet agents did not affect the incidence of radiological EH, hemorrhage, and thrombotic complications in patients undergoing cervical spinal surgery.
本研究旨在规范颈椎手术患者围手术期抗血小板药物的中断使用,并调查硬膜外血肿和血栓形成并发症的发生率。
本研究共纳入153例患者,其中男性85例,女性68例。他们的平均年龄为65.5岁。患者被分为两组:A组和B组。A组(139例患者)术前未接受抗血小板药物治疗,B组(14例患者)在术前7天或14天至术后3天恢复使用抗血小板药物。我们的分析包括术前人口统计学数据、术后基于磁共振成像的放射学硬膜外血肿(EH)评估以及术后症状性血肿、输血、中风和静脉血栓栓塞等并发症。
B组高血压、糖尿病和高脂血症等疾病的发生率显著高于A组。作为评估中风风险的临床预测规则的CHADS2评分,B组显著高于A组。相比之下,B组术中失血量显著低于A组。两组在放射学上严重的EH、出血和血栓形成并发症方面无显著差异。有趣的是,B组患者均未出现出血和血栓形成并发症。
我们对抗血小板药物的标准化围手术期管理并未影响颈椎手术患者放射学EH、出血和血栓形成并发症的发生率。